C115P: Lanadelumab Biosimilar, Human KLKB1 Monoclonal Antibody

Catalog No.: C115P | **Product Name:** Lanadelumab Biosimilar, Human KLKB1 Monoclonal Antibody

The research grade Lanadelumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

PRODUCT SPECIFICATIONS

Catalog No.	C115P
Product Name	Lanadelumab Biosimilar, Human KLKB1 Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Lanadelumab; X124-G01; DX-2930; KLKB1; anti-KLKB1
Summary	Recombinant Humanized IgG1 kappa Monoclonal Antibody.
Isotype	Human IgG1 kappa.
Source/Host	The anti-human KLKB1 monoclonal antibody lanadelumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade lanadelumab biosimilar specifically binds to the KLKB1 protein.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by lanadelumab.
Form Of Antibody	0.2 μM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The Lanadelumab Biosimilar, Human KLKB1 Monoclonal Antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Lanadelumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

REFERENCES & BACKGROUND

What is lanadelumab biosimilar research grade? Lanadelumab (trade name Takhzyro) is a fully human IgG1 kappa monoclonal antibody that specifically binds to and inhibits plasma kallikrein (KLKB1). Plasma kallikrein is a protease that cleaves high-molecular-weight kininogen to generate bradykinin, a potent mediator of vasodilation and vascular permeability. By inhibiting plasma kallikrein, lanadelumab reduces bradykinin production and thereby prevents angioedema attacks. Lanadelumab is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 2 years of age and older. Lanadelumab biosimilar uses the same protein sequences as the therapeutic antibody lanadelumab.